The rotavirus saga revisited

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 165-174

  Shaw, Alan R ^a  

^a Vedantra Pharmaceuticals   (United States)

Author keywords

diarrhea; intussusception; oral; vaccine

Indexed keywords

PLACEBO; PROTEIN VP4; PROTEIN VP7; RIBOSOME DNA; ROTAVIRUS VACCINE;

DEVELOPING COUNTRY; DIARRHEA; DISEASE SURVEILLANCE; DRUG APPROVAL; DRUG COST; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INFECTION RISK; INTESTINE INTUSSUSCEPTION; INTUSSUSCEPTION; MEDICAL DECISION MAKING; NICARAGUA; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; ROTAVIRUS; ROTAVIRUS INFECTION; UNITED STATES; VIRAL GASTROENTERITIS; VIRUS GENOME; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN;

HUMANS; INCIDENCE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; WORLD HEALTH;

EID: 84873033449     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-121511-093810     Document Type: Review

References (39)

1. Shaw A. 2006. The rotavirus vaccine saga. Annu. Rev. Med. 57:167-80
2. Chen J, Heyse JF, Heaton P, et al. 2010. Age dependence of the risk of intussusception following [corrected] rhesus-human reassortant rotavirus tetravalent vaccine: Is it beyond doubt? Am. J. Epidemiol. 171:1046-54
3. Vesikari T, Karvonen A, Forrest BD, et al. 2006. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr. Infect. Dis. J. 25:118-22
4. Lappalainen S, Ylitalo S, Arola A, et al. 2012. Simultaneous presence of human herpesvirus 6 and adenovirus infections in intestinal intussusception of young children. Acta Paediatr. 101:663-70
5. Vesikari T, Matson DO, Dennehy P, et al. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354:23-33
6. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. 2006. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354:11-22
7. Patton JT. 2012. Rotavirus diversity and evolution in the post-vaccine world. Discov. Med. 13:85-97
8. Ruiz LP Jr. 2006. Rotavirus vaccines. N. Engl. J. Med. 354:1747-51
9. Pitzer VE, Patel MM, Lopman BA, et al. 2011. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc. Natl. Acad. Sci. USA 108:19353-58
10. Kapikian AZ, Simonsen L, Vesikari T, et al. 2005. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J. Infect. Dis. 192(Suppl. 1):S22-29
11. Tate JE, Parashar UD. 2011. Monitoring impact and effectiveness of rotavirus vaccination. Expert Rev. Vaccines 10:1123-25
12. Staat MA. 2008. Delayed onset and diminished magnitude of rotavirus activity, United States, November 2007-May 2008. MMWR 57:697-700.
13. Payne DC, Staat MA, Edwards KM, et al. 2011. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin. Infect. Dis. 53:245-53
14. Clark HF, Lawley D, Mallette LA, et al. 2009. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin. Vaccine Immunol. 16:382-86
15. Giaquinto C, Jackson AE, Vesikari T. 2012. Report of the second European expert meeting on rotavirus vaccination. Vaccine 30:2237-44
16. Dennehy PH. 2012. Effects of vaccine on rotavirus disease in the pediatric population. Curr. Opin. Pediatr. 24:76-84
17. Cortes JE, Curns AT, Tate JE, et al. 2011. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N. Engl. J. Med. 365:1108-17
18. Sahni LC, Boom JA, Patel MM, et al. 2010. Use of an immunization information system to assess the effectiveness of pentavalent rotavirus vaccine in US children. Vaccine 28:6314-17
19. Boom JA, Tate JE, Sahni LC, et al. 2010. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 125:e199-207
20. Tate JE, Mutuc JD, Panozzo CA, et al. 2011. Sustained decline in rotavirus detections in theUnited States following the introduction of rotavirus vaccine in 2006. Pediatr. Infect. Dis. J. 30:S30-34
21. Curns AT, Panozzo CA, Tate JE, et al. 2011. Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr. Infect. Dis. J. 30:S54-55
22. O'Ryan M, Lucero Y, Linhares AC. 2011. Rotarix R: vaccine performance 6 years postlicensure. Expert Rev. Vaccines 10:1645-59
23. Snelling TL, Andrews RM, Kirkwood CD, et al. 2011. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin. Infect. Dis. 52:191-99
24. Mast TC, Khawaja S, Espinoza F, et al. 2011. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr. Infect. Dis. J. 30:e209-15
25. Patel M, Pedreira C, De Oliveira LH, et al. 2009. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301:2243-51
26. Victoria JG, Wang C, Jones MS, et al. 2010. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 84:6033-40
27. Gilliland SM, Forrest L, Carre H, et al. 2012. Investigation of porcine circovirus contamination in human vaccines. Biologicals 40:270-77
28. Ranucci CS, Tagmyer T, Duncan P. 2011. Adventitious agent risk assessment case study: evaluation of RotaTeq R-for the presence of porcine circovirus. PDA J. Pharm. Sci. Technol. 65:589-98
29. Dore DD, Turnbull BR, Seeger JD. 2012. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. Pharmacoepidemiol. Drug Saf. 21:415-19
30. Payne DC, Humiston S, Opel D, et al. 2011. A multi-center, qualitative assessment of pediatrician and maternal perspectives on rotavirus vaccines and the detection of porcine circovirus. BMC Pediatr. 11:83
31. Newall AT, Beutels P, Macartney K, et al. 2007. The cost-effectiveness of rotavirus vaccination inAustralia. Vaccine 25:8851-60
32. JitM, Edmunds WJ. 2007. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 25:3971-79
33. Dhont P, Trichard M, Largeron N, et al. 2008. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. J. Med. Econ. 11:431-48
34. Wu CL, Yang YC, Huang LM, Chen KT. 2009. Cost-effectiveness of childhood rotavirus vaccination in Taiwan. Vaccine 27:1492-99
35. Chotivitayatarakorn P, Poovorawan Y. 2010. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J. Trop. Med. Public Health 41:114-25
36. do Carmo GM, Yen C, Cortes J, et al. 2011. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 8:e1001024
37. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. 2010. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N. Engl. J. Med. 362:299-305
38. Kempe A, Patel MM, Daley MF, et al. 2009. Adoption of rotavirus vaccination by pediatricians and family medicine physicians in the United States. Pediatrics 124:e809-16
39. Daskalaki I, Spain CV, Long SS, Watson B. 2008. Implementation of rotavirus immunization in Philadelphia, Pennsylvania: high levels of vaccine ineligibility and off-label use. Pediatrics Pediatrics 122:e33-38